vs
Essent Group Ltd.（ESNT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Essent Group Ltd.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$312.4M vs $207.3M），Essent Group Ltd.净利率更高（49.6% vs -62.0%，领先111.6%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -0.8%），Essent Group Ltd.自由现金流更多（$848.7M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.3%）
Essentra PLC是一家面向全球市场的塑料及纤维产品供应商，总部位于英国牛津郡基德灵顿，业务网络覆盖全球多个区域，目前在伦敦证券交易所上市，可面向各行业客户提供多元化的相关产品及配套服务，在所属细分领域拥有较高的市场认可度。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
ESNT vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $312.4M | $207.3M |
| 净利润 | $155.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 59.1% | -54.7% |
| 净利率 | 49.6% | -62.0% |
| 营收同比 | -0.8% | 25.9% |
| 净利润同比 | -7.7% | 3.5% |
| 每股收益（稀释后） | $1.61 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $312.4M | $207.3M | ||
| Q3 25 | $311.8M | $159.9M | ||
| Q2 25 | $319.1M | $166.5M | ||
| Q1 25 | $317.6M | $139.3M | ||
| Q4 24 | $315.0M | $164.6M | ||
| Q3 24 | $316.6M | $139.5M | ||
| Q2 24 | $312.9M | $147.0M | ||
| Q1 24 | $298.4M | $108.8M |
| Q4 25 | $155.0M | $-128.6M | ||
| Q3 25 | $164.2M | $-180.4M | ||
| Q2 25 | $195.3M | $-115.0M | ||
| Q1 25 | $175.4M | $-151.1M | ||
| Q4 24 | $167.9M | $-133.2M | ||
| Q3 24 | $176.2M | $-133.5M | ||
| Q2 24 | $203.6M | $-131.6M | ||
| Q1 24 | $181.7M | $-170.7M |
| Q4 25 | 59.1% | -54.7% | ||
| Q3 25 | 63.9% | -106.9% | ||
| Q2 25 | 72.4% | -64.8% | ||
| Q1 25 | 65.2% | -102.6% | ||
| Q4 24 | 61.9% | -74.3% | ||
| Q3 24 | 65.6% | -94.6% | ||
| Q2 24 | 76.4% | -79.1% | ||
| Q1 24 | 71.6% | -151.9% |
| Q4 25 | 49.6% | -62.0% | ||
| Q3 25 | 52.7% | -112.8% | ||
| Q2 25 | 61.2% | -69.0% | ||
| Q1 25 | 55.2% | -108.5% | ||
| Q4 24 | 53.3% | -80.9% | ||
| Q3 24 | 55.6% | -95.7% | ||
| Q2 24 | 65.1% | -89.5% | ||
| Q1 24 | 60.9% | -156.8% |
| Q4 25 | $1.61 | $-1.28 | ||
| Q3 25 | $1.67 | $-1.81 | ||
| Q2 25 | $1.93 | $-1.17 | ||
| Q1 25 | $1.69 | $-1.57 | ||
| Q4 24 | $1.59 | $-1.34 | ||
| Q3 24 | $1.65 | $-1.40 | ||
| Q2 24 | $1.91 | $-1.52 | ||
| Q1 24 | $1.70 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.8B | $-80.0M |
| 总资产 | $7.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $5.8B | $-80.0M | ||
| Q3 25 | $5.7B | $9.2M | ||
| Q2 25 | $5.7B | $151.3M | ||
| Q1 25 | $5.7B | $144.2M | ||
| Q4 24 | $5.6B | $255.0M | ||
| Q3 24 | $5.6B | $346.8M | ||
| Q2 24 | $5.4B | $432.4M | ||
| Q1 24 | $5.2B | $140.3M |
| Q4 25 | $7.4B | $1.5B | ||
| Q3 25 | $7.4B | $1.2B | ||
| Q2 25 | $7.2B | $1.3B | ||
| Q1 25 | $7.2B | $1.3B | ||
| Q4 24 | $7.1B | $1.5B | ||
| Q3 24 | $7.1B | $1.5B | ||
| Q2 24 | $6.7B | $1.6B | ||
| Q1 24 | $6.6B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $856.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $848.7M | $-100.8M |
| 自由现金流率自由现金流/营收 | 271.7% | -48.6% |
| 资本支出强度资本支出/营收 | 2.4% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.52× | — |
| 过去12个月自由现金流最近4个季度 | $1.5B | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $856.1M | $-99.8M | ||
| Q3 25 | $215.9M | $-91.4M | ||
| Q2 25 | $189.5M | $-108.3M | ||
| Q1 25 | $221.6M | $-166.5M | ||
| Q4 24 | $861.5M | $-79.3M | ||
| Q3 24 | $229.2M | $-67.0M | ||
| Q2 24 | $188.7M | $-77.0M | ||
| Q1 24 | $216.9M | $-190.7M |
| Q4 25 | $848.7M | $-100.8M | ||
| Q3 25 | $210.6M | $-92.7M | ||
| Q2 25 | $188.8M | $-110.7M | ||
| Q1 25 | $221.3M | $-167.8M | ||
| Q4 24 | $854.8M | $-79.5M | ||
| Q3 24 | $228.7M | $-68.6M | ||
| Q2 24 | $187.6M | $-79.0M | ||
| Q1 24 | $212.5M | $-193.9M |
| Q4 25 | 271.7% | -48.6% | ||
| Q3 25 | 67.5% | -58.0% | ||
| Q2 25 | 59.2% | -66.5% | ||
| Q1 25 | 69.7% | -120.5% | ||
| Q4 24 | 271.3% | -48.3% | ||
| Q3 24 | 72.2% | -49.2% | ||
| Q2 24 | 60.0% | -53.7% | ||
| Q1 24 | 71.2% | -178.2% |
| Q4 25 | 2.4% | 0.5% | ||
| Q3 25 | 1.7% | 0.8% | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.1% | 1.0% | ||
| Q4 24 | 2.1% | 0.1% | ||
| Q3 24 | 0.2% | 1.2% | ||
| Q2 24 | 0.3% | 1.4% | ||
| Q1 24 | 1.5% | 3.0% |
| Q4 25 | 5.52× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 0.97× | — | ||
| Q1 25 | 1.26× | — | ||
| Q4 24 | 5.13× | — | ||
| Q3 24 | 1.30× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 1.19× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESNT
| Mortgage Insurance Segment | $192.4M | 62% |
| Other | $120.0M | 38% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
